TAILORx: Phase 3 trial validating a 21-gene expression assay in breast cancer

Clifford Hudis

At the European Cancer Congress (ECC) 2015, Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, discusses the low-risk registry results from Trial Assigning IndividuaLized Options for Treatment (TAILORx), which is a prospective phase 3 clinical trial designed to evaluate the role of endocrine therapy and chemoendocrine therapy in patients with oestrogen receptor (ER)-positive, HER2-negative, axillary node-negative breast cancer whose treatment was guided by the 21-gene expression assay results, the Oncotype DX® Breast Cancer Assay Recurrence Score® results.

Share this video  
25th September 2015